AAP
LCTX icon

Ardsley Advisory Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Ardsley Advisory Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-18,585
Closed -$45K – 171
2015
Q3 		$45K Hold
18,585
– – 0.01% 143
2015
Q2 		$54K Hold
18,585
– – 0.01% 160
2015
Q1 		$75K Buy
+18,585
New +$64.3K 0.01% 185

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ardsley Advisory Partners's LCTX Position: Q4 2015 in Review

Ardsley Advisory Partners sold out of Lineage Cell Therapeutics (LCTX) in Q4 2015, closing a stake of 18,585 shares — an estimated $45K sold.

Ardsley Advisory Partners first reported a position in LCTX in Q1 2015 and held it in 3 quarters. The position peaked at $75K in Q1 2015. 68 funds tracked by Wall St. Rank hold LCTX as of Q4 2015.

  • Ardsley Advisory Partners reported no remaining Lineage Cell Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Ardsley Advisory Partners sold 18,585 Lineage Cell Therapeutics shares in Q4 2015, an estimated $45K.
  • Ardsley Advisory Partners first reported a position in Lineage Cell Therapeutics in Q1 2015 and held it in 3 quarters.
  • Ardsley Advisory Partners's Lineage Cell Therapeutics position peaked at $75K in Q1 2015.
  • 68 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2015.

Based on Ardsley Advisory Partners's 13F filing for Q4 2015, filed 16 Feb 2016.